PRQR ProQR Therapeutics N.V.

13.24
-0.76  -5%
Previous Close 14
Open 13.97
Price To Book 4.43
Market Cap 512787632
Shares 38,715,563
Volume 125,197
Short Ratio
Av. Daily Volume 329,827

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 1/2 trial to be completed 2H 2019. Phase 2/3 pivotal trial to commence 1H 2019.
QR-010
Leber's Congenital Amaurosis (LCA) - Genetic blindness
Phase 1b top-line data released September 25, 2017. FEV levels not significant across four doses. One of four doses showed significance in subgroup.
QR-010
Cystic Fibrosis
Phase 1/2 interim data due early 2019.
QR-313
Epidermolysis bullosa
Phase 1/2 trial to be initiated 2019.
QR-1123
autosomal dominant retinitis pigmentosa (adRP)
Phase 1/2 trial to be initiated in the coming months with data due mid-2019.
QR-421a - STELLAR
Usher Syndrome Type 2